• Infant Bacterial Therapeutics posted a wider operating loss of SEK 30.11 million in Q2, net sales unchanged at no revenue.
• Loss per share widened to SEK 2.21.
• For H1, operating loss widened to SEK 53.61 million, loss per share deepened to SEK 3.91.
• Cash fell to SEK 108.6 million at June 30, total assets declined to SEK 120.22 million.
• EMA said IBT fulfilled its Pediatric Investigational Plan; FDA completed review of Phase II/III data ahead of a planned pre-BLA meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Infant Bacterial Therapeutics AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.